Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > SABC 2024 - Irene Study Results - Pelareorep in TNBC

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Nov 02, 2024 11:23pm

176 Views

Post# 36294051

SABC 2024 - Irene Study Results - Pelareorep in TNBC

Poster Session 1

12:30 – 2:00 p.m.

Wednesday, December 11

P1-09-19: IRENE study: Phase 2 study of oncolytic virus pelareorep and PD-1 inhibitor retifanlimab in metastatic triple negative breast cancer - Principal Investigator: Mridula George

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?